This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Stephen K. Tyring, MD, PhD
Galveston, Tex

Arch Intern Med. 1994;154(18):2109.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Recent attention has been focused on new antiviral agents for the treatment of herpes zoster both in the medical literature¹ and in the lay press (Wall Street Journal. July 12, 1933;B1, 5). Since acyclovir was approved for treatment of herpes zoster in April 1990, we have kept a log at the University of Texas Medical Branch, Galveston, of patients presenting at our clinics who inform us that they were previously treated for shingles by their local physician. Interestingly, only 33 (17%) of 197 of these patients had received acyclovir at the recommended dosage of 800 mg orally five times per day for 7 to 10 days. Another 56% of the patients reported being treated with acyclovir at lower oral dosages and/or with topical acyclovir. The remaining 27% of patients were treated with oral antibacterial agents and/or a variety of other non-antiviral drugs.

As we actively enroll patients in clinical . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?